EU agency backs new cancer drugs from Roche and Algeta/Bayer
LONDON, Sept 20
LONDON, Sept 20 (Reuters) - European regulators have recommended approval of Roche's new breast cancer drug Kadcyla and a prostate cancer medicine, Xofigo, from Algeta and Bayer.
The European Medicines Agency (EMA) said on Friday its experts had also backed Johnson & Johnson's diabetes drug Invokana and Gilead's HIV treatment Viteka.
Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Storm to cloak Midwest to Northeast in snow, freezing rain
- Twitter backtracks on block feature after users revolt |